1
|
Neri S, Ascoli M, Africa E, Versace P, Porcelli A, Armentano A, Santangelo D, Pascarella A, Manzo L, Lobianco C, Mastroianni G, Cianci V, Gasparini S, Aguglia U, Ferlazzo E. The relevance of MRI blood-sensitive sequences in the diagnostic assessment of late-onset epilepsy. Eur Rev Med Pharmacol Sci 2022; 26:1178-1182. [PMID: 35253174 DOI: 10.26355/eurrev_202202_28110] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/14/2023]
Abstract
OBJECTIVE Sporadic cerebral amyloid angiopathy (CAA) is a degenerative brain small vessel disease of ageing resulting from progressive amyloid deposition in small arteries and arterioles of the cortex and leptomeninges. CAA may be diagnosed by the mean of Boston criteria, particularly with the use of the blood-sensitive T2* MRI sequences (GRE and SWI). Epileptic seizures have rarely been reported in CAA. PATIENTS AND METHODS We describe two patients with late-onset unprovoked seizures due to CAA. A short literature review on this topic is presented. RESULTS In our two patients with late-onset unprovoked seizures as the first manifestation of CAA, only GRE and SWI sequences lead to a correct diagnosis. In literature, only 15 patients with CAA presenting with seizures have been reported. In these subjects, data on seizures semiology and prognosis are scarce. CONCLUSIONS Our report highlights the importance to perform blood-sensitive sequences in all subjects with LOE of otherwise unknown etiology, not to miss a diagnosis of CAA.
Collapse
Affiliation(s)
- S Neri
- Department of Medical and Surgical Sciences, Magna Græcia University of Catanzaro, Catanzaro, Italy.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
2
|
Robesti D, Gandaglia G, Fossati N, Cucchiara V, Nocera L, Barletta F, Scuderi S, Rizzo A, Zito E, Gallina A, Camisassa E, Sciacqua L, Santangelo D, Droghetti M, Sorce G, Pellegrino F, Mazzone E, Stabile A, Bravi C, Martini A, Karakiewicz P, Moschini M, Montorsi F, Briganti A. A positive PSMA PET/CT predicts more aggressive disease progression in patients with biochemical recurrence after radical prostatectomy. EUR UROL SUPPL 2020. [DOI: 10.1016/s2666-1683(20)33768-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022] Open
|
3
|
Verderame F, Russo A, Di Leo R, Badalamenti G, Santangelo D, Cicero G, Valerio MR, Gulotta G, Tomasello G, Gebbia N, Fulfaro F. Gemcitabine and oxaliplatin combination chemotherapy in advanced biliary tract cancers. Ann Oncol 2006; 17 Suppl 7:vii68-72. [PMID: 16760298 DOI: 10.1093/annonc/mdl955] [Citation(s) in RCA: 43] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/08/2023] Open
Abstract
BACKGROUND Biliary tract cancers are uncommon tumors with a poor prognosis and most patients present with invasive and inoperable disease at diagnosis. Chemotherapy represents a palliative treatment, with poor response rates and a median survival of less than 6 months. Oxaliplatin and gemcitabine have shown an interesting activity as single agents in this group of patients. PATIENTS AND METHODS We carried out a multicenter phase II study to evaluate the efficacy and safety of combined oxaliplatin and gemcitabine in locally advanced and metastatic biliary tract carcinoma. The schedule of chemotherapy included oxaliplatin 100 mg/m(2) on day 1 and gemcitabine 1000 mg/m(2) on days 1 and 8, every 21 days. RESULTS All the 24 patients were evaluable for response and toxicity. According to RECIST criteria we observed one complete response and 11 partial responses for an overall response rate of 50%. Overall survival for all the patients on study was 12 months (range 2-30). According to WHO criteria, three patients (12.5%) suffered grade 3 neutropenia and three patients (12.5%) grade 3 thrombocytopenia. Only two patients (8%) suffered grade 3 neuropathy. CONCLUSIONS Oxaliplatin and gemcitabine chemotherapy seems to be effective with a favorable safety profile in first-line chemotherapy of advanced biliary tract cancers.
Collapse
Affiliation(s)
- F Verderame
- Department of Medicine, Oncology Unit, Azienda Ospedaliera Giovanni Paolo II Sciacca (AG), Palermo, Italy
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
4
|
Gebbia N, Verderame F, Di Leo R, Santangelo D, Cicero G, Valerio MR, Arcara C, Badalamenti G, Fulfaro F, Carreca I. A phase II study of oxaliplatin (O) and gemcitabine (G) first line chemotherapy in patients with advanced biliary tract cancers. J Clin Oncol 2005. [DOI: 10.1200/jco.2005.23.16_suppl.4132] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- N. Gebbia
- Dept of Oncology, Palermo, Sicily, Italy; Azienda Osp, Sciacca, Italy; Dept of Experim and Clin Onc, Palermo, Sicily, Italy
| | - F. Verderame
- Dept of Oncology, Palermo, Sicily, Italy; Azienda Osp, Sciacca, Italy; Dept of Experim and Clin Onc, Palermo, Sicily, Italy
| | - R. Di Leo
- Dept of Oncology, Palermo, Sicily, Italy; Azienda Osp, Sciacca, Italy; Dept of Experim and Clin Onc, Palermo, Sicily, Italy
| | - D. Santangelo
- Dept of Oncology, Palermo, Sicily, Italy; Azienda Osp, Sciacca, Italy; Dept of Experim and Clin Onc, Palermo, Sicily, Italy
| | - G. Cicero
- Dept of Oncology, Palermo, Sicily, Italy; Azienda Osp, Sciacca, Italy; Dept of Experim and Clin Onc, Palermo, Sicily, Italy
| | - M. R. Valerio
- Dept of Oncology, Palermo, Sicily, Italy; Azienda Osp, Sciacca, Italy; Dept of Experim and Clin Onc, Palermo, Sicily, Italy
| | - C. Arcara
- Dept of Oncology, Palermo, Sicily, Italy; Azienda Osp, Sciacca, Italy; Dept of Experim and Clin Onc, Palermo, Sicily, Italy
| | - G. Badalamenti
- Dept of Oncology, Palermo, Sicily, Italy; Azienda Osp, Sciacca, Italy; Dept of Experim and Clin Onc, Palermo, Sicily, Italy
| | - F. Fulfaro
- Dept of Oncology, Palermo, Sicily, Italy; Azienda Osp, Sciacca, Italy; Dept of Experim and Clin Onc, Palermo, Sicily, Italy
| | - I. Carreca
- Dept of Oncology, Palermo, Sicily, Italy; Azienda Osp, Sciacca, Italy; Dept of Experim and Clin Onc, Palermo, Sicily, Italy
| |
Collapse
|
5
|
Bajetta E, Del Vecchio M, Nova P, Gattinoni L, Santinami M, Santangelo D, Daponte A, Sertoli M, Queirolo P, Bernengo M. 837 Multicenter phase III randomized trial of polychemotherapy (CVD regimen) versus the same chemotherapy (CT) plus subcutaneous (SC) interleukin-2 (IL-2) and interferon-alpha-2b (IFN) in metastatic melanoma. EJC Suppl 2003. [DOI: 10.1016/s1359-6349(03)90863-9] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022] Open
|